Alector Inc (Alector) is a biotechnology company that develops therapies for the immune system to cure neurodegeneration and cancer. The company discovers and develops immune-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. It combines state-of-the-art antibody technology and recent discoveries in neuroimmunology and oncology to fight cancer. Alector also generates and validates antibody drugs that are into disease-altering and genetically validated neuroimmune targets. The company develops drugs through collaborations with scientists and drug developers. It operates a manufacturing facility in Milpitas, California. Alector is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
131 Oyster Point Blvd., Suite 600, South San Francisco, California, 94080
Website
alector.com
Telephone
1 415 2315660
No of Employees
244
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALEC (NASD)
Revenue (2022)
$97.1M
-27.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
2.2%
(2022 vs 2021)
Market Cap*
$485.5M
Net Profit Margin (2022)
XYZ
-34.7%
(2022 vs 2021)
* As of and is in US$
Alector Inc premium industry data and analytics
Products and Services
| Services |
|---|
| Services |
| Drug Discovery |
| Antibody Drugs Validation |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Alector Inc | Denali Therapeutics Inc | Allele Biotechnology and Pharmaceuticals Inc | AZTherapies Inc | Caraway Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | South San Francisco | San Diego | Boston | Cambridge |
| State/Province | California | California | California | Massachusetts | Massachusetts |
| No. of Employees | 244 | 445 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tillman Gerngross | Chairman | Executive Board | 2013 | 59 |
| Arnon Rosenthal | Director; Chief Executive Officer | Executive Board | 2013 | 68 |
| Marc Grasso | Chief Financial Officer | Senior Management | 2022 | 50 |
| Clare Hunt | Chief People Officer | Senior Management | - | - |
| Gary Romano | Chief Medical Officer | Senior Management | - | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward